Baxter International Inc (NYSE:BAX) Shares Bought by Tdam USA Inc.

Tdam USA Inc. boosted its position in shares of Baxter International Inc (NYSE:BAX) by 11.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,903 shares of the medical instruments supplier’s stock after buying an additional 498 shares during the quarter. Tdam USA Inc.’s holdings in Baxter International were worth $402,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Westpac Banking Corp boosted its position in Baxter International by 5.0% during the second quarter. Westpac Banking Corp now owns 256,418 shares of the medical instruments supplier’s stock worth $21,001,000 after acquiring an additional 12,276 shares during the last quarter. Sector Gamma AS boosted its position in Baxter International by 3.1% during the second quarter. Sector Gamma AS now owns 462,305 shares of the medical instruments supplier’s stock worth $37,863,000 after acquiring an additional 14,077 shares during the last quarter. CWM LLC boosted its position in Baxter International by 40.8% during the second quarter. CWM LLC now owns 2,240 shares of the medical instruments supplier’s stock worth $183,000 after acquiring an additional 649 shares during the last quarter. AGF Investments LLC boosted its position in Baxter International by 37.1% during the second quarter. AGF Investments LLC now owns 4,080 shares of the medical instruments supplier’s stock worth $334,000 after acquiring an additional 1,104 shares during the last quarter. Finally, KBC Group NV boosted its position in Baxter International by 57.3% during the second quarter. KBC Group NV now owns 438,163 shares of the medical instruments supplier’s stock worth $35,886,000 after acquiring an additional 159,694 shares during the last quarter. Institutional investors own 83.96% of the company’s stock.

A number of equities analysts recently weighed in on BAX shares. Wells Fargo & Co set a $95.00 price target on shares of Baxter International and gave the stock a “buy” rating in a research report on Friday, July 26th. Piper Jaffray Companies boosted their price target on shares of Baxter International from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Thursday, July 25th. Royal Bank of Canada set a $87.00 price target on shares of Baxter International and gave the stock a “hold” rating in a research report on Friday, July 26th. JPMorgan Chase & Co. boosted their price target on shares of Baxter International from $80.00 to $88.00 and gave the stock an “overweight” rating in a research report on Monday, May 13th. Finally, KeyCorp assumed coverage on shares of Baxter International in a research report on Tuesday, June 25th. They set a “sector weight” rating on the stock. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Baxter International has an average rating of “Buy” and a consensus price target of $85.27.

In other news, Director John D. Forsyth sold 1,320 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $78.21, for a total value of $103,237.20. Following the sale, the director now directly owns 32,779 shares of the company’s stock, valued at approximately $2,563,645.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jacqueline Kunzler sold 593 shares of the business’s stock in a transaction that occurred on Wednesday, June 19th. The shares were sold at an average price of $80.46, for a total transaction of $47,712.78. Following the completion of the sale, the senior vice president now directly owns 9,023 shares in the company, valued at $725,990.58. The disclosure for this sale can be found here. 0.70% of the stock is currently owned by insiders.

BAX stock traded up $0.98 during trading on Thursday, reaching $86.82. 38,200 shares of the stock were exchanged, compared to its average volume of 2,377,217. The company has a quick ratio of 2.10, a current ratio of 2.78 and a debt-to-equity ratio of 0.72. The stock has a 50 day simple moving average of $83.41. Baxter International Inc has a 1 year low of $61.05 and a 1 year high of $88.28. The stock has a market cap of $43.70 billion, a price-to-earnings ratio of 28.52, a price-to-earnings-growth ratio of 1.98 and a beta of 1.00.

Baxter International (NYSE:BAX) last issued its earnings results on Thursday, July 25th. The medical instruments supplier reported $0.89 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.08. Baxter International had a net margin of 14.28% and a return on equity of 21.21%. The company had revenue of $2.84 billion for the quarter, compared to the consensus estimate of $2.80 billion. During the same period in the previous year, the firm earned $0.77 earnings per share. Baxter International’s quarterly revenue was down .1% compared to the same quarter last year. Sell-side analysts expect that Baxter International Inc will post 3.37 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 1st. Stockholders of record on Friday, August 30th will be paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 1.01%. The ex-dividend date is Thursday, August 29th. Baxter International’s dividend payout ratio (DPR) is 28.85%.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Further Reading: Do equity income investments outperform growth and income investments?

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.